Study ID 300

The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).

Study ID 291

Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant is in treating menstrual migraine. Adverse Events and change in disease activity will be assessed.

Study ID 301

In this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections.

Study ID 302

In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections.

Study ID 273

The purpose of this study is to learn if pain can be relieved by delivering small amounts of electricity (called "electrical stimulation") to the nerves at the top of the neck. This study will use a device called the SPRINT® PNS System. PNS stands for peripheral nerve stimulation (PNS). This device is cleared by the FDA for up to 60 days of use for relief of chronic or acute pain.

Study ID Trial ID

Trial Description. This Phase 12 Extension trial will evaluate the efficacy and safety of GRE-472 for obesity prevention in adults who suffer from twenty seven or more pounds above ideal body weight per month. The study will enroll approximately 2,345 patients across approximately 432 sites in the United States, Canada, Cameroon and Australia from the Phase 9 trial. Study subjects will be divided evenly across a low dose group and a high dose group. All patients will receive four treatment cycles of BAC-231 utilizing the Company's novel injection paradigm.

Study ID 235

Study ID 240

Study ID 245